PRKACB and colorectal cancer: Consistent with previous studies 30, our study showed that PRKACB had a significant discrepancy of expression in normal and tumor tissues of colorectal cancer, and we also depicted that down-regulation of PRKACB expression is a risk factor for declining 1, 3, and 5-year survival rates in patients with CRC.